Lung Cancer (NSCLC) Clinical Trials
7 recruiting trials for Lung Cancer (NSCLC). Eligibility criteria explained in plain English.
TrialFinderData lists 7 Lung Cancer (NSCLC) clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 2 is the largest group at 33% (2 studies); the largest phase groups are Phase 2: 2, Phase 1: 2, Phase 2 / Phase 3: 1, Phase 1 / Phase 2: 1.
Research is led by Rigshospitalet, Denmark (1), National Taiwan University Clinical Trial Center (1), Guangdong Provincial People's Hospital (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Dexamethasone (drug, 1 trial), followed by In vitro culture of autologous dendritic and natural killer cells for the treatment of patients with non-small cell lung cancer, Postoperative EGFR-TKI Therapy.
Track Lung Cancer (NSCLC) trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
High Dose Dexamethasone to Reduce Postoperative Pain After Video-Assisted Thoracoscopic Surgery Lobectomy /Segmentectomy
The aim is to conduct a randomized controlled trial (RCT) with a high dose arm (1mg/kg) vs a low dose (8mg in total) of steroid (Dexamethasone) given intravenous (IV) after the...
DC/NK Cell Therapy
Primary Outcomes The primary objective of this trial is to test the safety of formulations containing dendritic cells (DCs) and natural killer (NK) cells cultured in vitro. By...
Association Between RVT and Prognosis After Neoadjuvant Targeted Therapy in EGFR NSCLC
EGFR-mutated NSCLC is a distinct subtype that responds well to targeted therapies. Neoadjuvant targeted therapy aims to downstage tumors and improve surgical outcomes, but the...
Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501）
Background Synchronous multifocal primary lung cancer (sMPLC) presents a therapeutic challenge, particularly for bilateral lesions. While surgical resection is standard for...
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
The Sponsor is developing KB707, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector designed to stimulate an anti-tumor immune response...
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
The goal of this clinical trial is to evaluate whether TJ101, an investigational antibody-drug conjugate (ADC), can safely and effectively treat patients with advanced solid...
A Study of SH009 Injection in Patients With Advanced Solid Tumors.
Evaluate the efficacy and safety of SH009 injection therapy for patients with advanced solid tumors
Explore Other Conditions
Frequently Asked Questions
There are currently 7 clinical trials for Lung Cancer (NSCLC), with 7 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Lung Cancer (NSCLC), review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Lung Cancer (NSCLC), representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.